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Non-small cell lung cancer (NSCLC) comprises predominantly squamous, adenocarcinomas and large cell undifferentiated tumours. Only 5% of such tumours are curable by surgery (Crofton & Douglas, 1981) , and up to 60% are inoperable at the time of diagnosis (Crofton & Douglas, 1981) . Chemotherapy is relatively ineffective, with a 17% response rate and no long-term survival (Simes, 1985) . Radiotherapy also is rarely curative (Kjaer, 1982) . Survival in NSCLC is related to the degree of spread of the tumour at diagnosis, staged by the tumour nodal involvement metastasis (TNM) system (Mountain et al., 1974) .
A characteristic of malignant cells in culture is a decreased requirement for serum or supplemental growth factors (Holley, 1975) . This suggests that malignant cells may secrete growth factors into their medium. Sporn and Todaro (1980) have suggested the term autocrine growth regulation to describe the situation where a cell secretes a factor, possesses specific receptors for the factor and responds to that factor.
Epidermal growth factor (EGF) is a growth promoting agent found in normal human plasma and tissues which acts by binding to receptors for the hormone on cell surfaces. When injected into newborn mice, EGF elicits the proliferation and differentiation of the epidermis (Cohen, 1983) . In tissue culture, EGF induces the proliferation of a wide variety of cell types, including keratinocytes and transformed epithelial cells (Carpenter & Cohen, 1979) . EGF receptor (EGFr) has three parts, an external domain, a transmembrane portion and an internal domain. On binding with its receptor, EGF leads to activation of a tyrosine kinase on the internal domain of the receptor (Carpenter & Cohen, 1979) , a property shared with the protein product of some oncogenes. Indeed the erb-B oncogene product is a truncated EGFr (Downward et al., 1984) . The receptor is also internalised after stimulation.
Peptide growth factors produced by transformed cells include transforming growth factor oc (TGF-ax), which is structurally related to EGF and binds to the EGF receptor (EGFr) (Marquardt et al., 1983) and transforming growth factor (TGF,B) which binds to different receptors but is synergistic with TGFax (Marquardt et al., 1983) .
In breast cancer, it has been shown that the level of EGFr is associated with metastatic potential, with poorly differentiated tumours and with a poor prognostic subgroup (Sainsbury et al., 1985a) . The level of EGFr is also associated with the degree of invasion and poor differentiation of bladder cancer (Neal et al., 1985) . EGFr have been found on NSCLC cell lines grown in cell culture (Sherwin et al., 1981 (DeLeMis et al., 1979 ) with a murine monoclonal antibody (EGFR1) (gift of Dr M. Waterfield). The antibody was raised from an epidermoid carcinoma cell line (A431) which expresses a high concentration of EGF receptors (Waterfield et al., 1982) .
Five um cryostat sections were cut and picked up on lysine-coated slides. After drying with a fan for 30min, they were fixed in acid for 20 min and washed twice for 5 min in saline buffered to pH 7.6 with tris-HCl. The sections were then covered with normal serum (diluted 1:4 with trisbuffered saline) as a blocking agent for 10min. The sections were incubated at room temperature with primary antibody for 30 min. After two washes in tris-buffered saline, the blocking step was repeated. The sections were then incubated with peroxidase-conjugated rabbit anti-mouse immunoglobulin (Dakopatts) for 30 min. After two further 5-min washes, peroxidase activity was developed by means of a solution of diaminobenzidine. The sections were washed in water, counterstained with haemaoxylin, dehydrated and mounted. The positive control was human placenta, which contains large numbers of EGFr. For negative controls we omitted the primary antibody. Controls used in each run showed similar intensity of staining.
The intensity of staining was assessed by two observers reading the sections independently without knowledge of the tumour stage or degree of differentiation. The sections were graded on a scale from 0 to + + + according to the intensity of staining of malignant cells relative to the positive control. The placental control stained strongly positively on all occasions and showed no staining when the primary antibody was omitted. The histological typing of the tumours was carried out on paraffin sections of the resected material. Statistical analysis was performed using the chi-square test on a two by four table of results.
Results
Normal lung and bronchus EGFr Results of staining for EGFr in 17 specimens of normal lung showed no staining in 5 specimens and mild staining (1 +) in 9. Only two specimens of normal lung tissue showed moderate staining graded + +, while one specimen had strong staining for EGFr. In normal bronchial epithelium there was strong positive staining for EGFr in a thin band in the basal layer (Figure 1 ) and weaker staining in bronchial glands. Table  I , and illustrated in Figure 2 . Staining in sections from different parts of the tumour showed a good correlation of intensity of EGFr staining in 10 cancers examined. Eight of 10 tumours examined had identical grading from different ar_ea. aN tumour grAde EGFr ngate was the-n g.rad.ed positive but one tumour which graded positive was subsequently negative.
Twenty-seven of forty squamous tumours stained moderately strongly or strongly (+ + or + + +), while only nine of twenty adenocarcinomas stained similarly. Overall, the staining in squamous tumours was significantly stronger (Table III) .
When all the tumours were divided according to degree of differentiation (well and moderately differentiated versus poorly differentiated), there was no significant difference in intensity of staining for EGFr between the groups. Likewise squamous tumours alone showed no significant relationship between EGFr score and degree of differentiation, although there were only two well differentiated squamous tumours. There was no statistically significant difference in the degree of differentiation in different stages of tumour spread.
Discussion
We have demonstrated the presence of epidermal growth factor receptors in non-small cell lung cancer and the fact that squamous carcinomas show more staining than nonsquamous tumours. We have also shown that the intensity of staining for EGFr is related to the stage of spread of the tumours. The histology of NSCLC can vary throughout the tumour (Mountain et al., 1974) and thus we have taken samples from different areas of the tumours and found no significant variation of staining within tumours. Hendler and Ozanne (1984) demonstrated EGFr in 11 squamous lung cancers. They showed that 7 of 8 adenocarcinomas failed to stain for EGFr, using a semiquantitative autoradiography technique. The greater intensity of staining for EGFr in squamous tumours is consistent with the findings that squamous tumours at other sites, such as head and neck or cervical cancer, and squamous carcinoma cell lines express more EGF receptors than other cancers . Ozanne et al. have shown a 2 to 10-fold excess of receptor sites in squamous cancers of various sites, including lung, compared to normal skin .
In our series, normal lung showed far less staining for EGFr, and only 1/17 normal lungs were strongly positive. This may reflect individual variation or possibly EGFr involvement in other chronic inflammatory processes.
Our results suggest that epidermal growth factor receptor may play a part in the genesis or spread of lung cancers. This is the third common primary carcinoma in which we have found a correlation of the presence of EGFr with some of the prognostic features (Neal et al., 1985; Sainsbury et al., 1985b) . This may suggest that, rather than EGFr being involved in tumour initiation, subclones of tumours that express more EGFr or have had rearrangement of EGFr genomic DNA may be selected for growth, invasion and metastasis. This may be a relatively late change in tumour development. Cerny et al. (1986) examined 63 lung tumours, mainly bronchial biopsies, and found 86% of squamous cancers stained positively for EGFr, but none of 15 small cell tumours stained. However, only 5 adenocarcinomas or large cell tumours were examined and the relation to stage was not assessed. Neal et al (1985) showed that staining for EGFr was related to poor differentiation of bladder cancers, and Sainsbury et al. (1985b) found a similar relationship in breast cancers, but we did not observe this in our specimens. In our series of bronchial tumours, there was no significant association of differentiation with stage and this may be a reflection of the large proportion of tumours that were moderately or poorly differentiated. Indeed in adenocarcinoma of the bronchus there is no significant survival difference as regards degree of differentiation (Katlic & Carter, 1979) .
The detection of normal basal cells in the bronchial mucosa staining for EGFr, first reported by Gusterson et al. (1984) , suggests that these stem cells of the mucosa may require EGF for proliferation and differentiation to normal mucosal cells. If these cells are the site of transformation for lung cancers, it would be expected that some adenocarcinomas and large cell tumours would also express EGFr, as we have found, in contrast to Ozanne's group .
The demonstration of a high concentration of EGFr in the worse prognosis NSCLC suggests a novel potential target for therapy. To quantitate the binding characteristics, we have assayed membranes from these primary tumours and have found high affinity sites (Kd 1 x 10-molar) for EGF and much higher numbers of receptors than breast cancers (190 fmol mg-' membrane protein versus 4-47 fmol mg-' membrane protein) (Sainsbury et al., 1985a) . EGF bound drug would be expected to react specifically at these sites, thus leading to higher concentration of drug in tumour than in other tissue. Drugs linked to EGF should be more selective than current therapies, particularly as receptor stimulation is linked to internalisation, and squamous tumours express several-fold more EGFr than reported for other normal tissues, including normal keratinocytes (Ozanne et al., 1985) .
The monoclonal antibody used here recognises the external domain of the EGFr, so this could also be used for targeting. The relationship of EGFr to other prognostic features in three common primary tumours shows that this type of drug therapy might be generally applicable in patients in whom there is little alternative therapy at present. We are currently studying this approach in human non-small cell cancer lines.
